LTRN Lantern: Company Value to Revenue Ratio

Lantern (LTRN) - corporate logo

Lantern Pharma Inc. (LTRN) is implementing the RADR AI system for high-precision modeling of lung cancer therapy. The EV-to-revenue multiple visualizes the market value of the debt-free business, where the latest parameter stands at 0.00. Synergy with research institutes and cloud services optimizes patient selection. Growing demand for predictive platforms is expanding the customer base among pharmaceutical developers.

LTRN (Lantern) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

LTRN (Lantern Pharma Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental valuation:Lantern LTRN
Product sample of Lantern Pharma

To objectively evaluate Lantern Pharma Inc. (LTRN), it is necessary to analyze the enterprise value relative to sales, excluding debt load. The EV/Sales trend reflects the market price of assets per unit of revenue, allowing for a determination of the overvaluation of the AI platform for targeted drug discovery. This helps investors decouple speculative interest in cancer therapy innovations from the actual capitalization of the company's fundamental potential.